Publications
Return to Publications Listing
C-MAP™ Canadian Drug Benefit Plans Reference Guide
Order Form | Frequently Asked Questions
C-MAP™ Canadian Drug Benefit Plans Reference Guide 2012 Edition
Ninety per cent of Canadians have some form of drug plan coverage. However, staying up-to-date with the policies and requirements of the various reimbursement schemes is a challenging but necessary requirement for gaining access to the multi-billion dollar Canadian market. This comprehensive reference guide is an essential tool for developing and maintaining a clear understanding of Canada's public and private sector drug plans.
The Canadian Market Access for Pharmaceuticals (C-MAP™) Canadian Drug Benefit Plans Reference Guide 2012 Edition provides detailed information on the formulary listing policies and procedures of the 10 provincial prescription drug programs and includes separate chapters on 4 federal drug programs. There are also detailed overviews of the Provincial Cancer Programs, the pan-Canadian Oncology Drug Review (formerly the Joint Oncology Drug Review), the Patented Medicine Prices Review Board (PMPRB), the Canadian Agency for Drugs and Technologies in Health (CADTH), Federal/ Provincial/ Territorial Initiatives, and the private drug plans in Canada. An extensive section on the Common Drug Review (CDR) provides a comprehensive description of the CDR process including CDR rationale for the Canadian Drug Expert Committee (CDEC) (formerly the Canadian Expert Drug Advisory Committee) decisions, time to decision tracking of submissions, and CDR submission forms and templates available online. The executive summary provides essential facts on each of the drug plans in a convenient tabular format. The 2012 Edition also includes new sections on Blood Agencies and Public Health Vaccines.
In addition, a new feature of the 2012 Edition is an executive briefing on the Pharmaceutical Pricing and Reimbursement Landscape in Canada. This special report provides an overview of the Canadian pharmaceutical pricing and reimbursement environment. It includes descriptions of the health care system and pharmaceutical market, and also discusses pharmaceutical pricing including the Patented Medicine Prices Review Board guidelines and procedures, and the reimbursement environment including the Common Drug Review, INESSS in Quebec and the newly formed pan-Canadian Oncology Drug Review.
This publication is divided into a 2-volume set. Volume 1 contains comprehensive details of the various Canadian drug benefit plans. Volume 2 provides formulary submission requirements, deadlines, contacts, and checklists for CDR and non-CDR submissions.
This publication includes, but is not restricted to:
- Identification of each provincial drug plan or selected federal program
- Detailed description of each plan
- Identification of the governing acts and regulations
- Drug plan expenditures and use profile
- Formulary descriptions
- Summaries of processes and procedures for listing and approval
- Special authorization processes
- Reimbursement regulations and procedures
- Requirements for manufacturers’ submissions to the Common Drug Review and directly to the provincial drug plans including generic products
- A description of the Special Drug Programs for each province
- Reporting structure within each province
- A PMPRB section including highlights of the revised Guidelines to be implemented on January 1, 2010 and latest changes in the PMPRB processes. The section will present more in depth details on the PMPRB rules and regulations..
- A glossary of terms
- PDCI Market Access online version of C-MAP™ Canadian Drug Benefit Plans Reference Guide
Notification of any major changes will be sent by email on an ongoing basis. In addition, thorough updates will be sent quarterly via email to ensure that all changes are captured.
Subscribers also receive unlimited password-protected access to the online electronic version of C-MAP™ Canadian Drug Benefit Plans Reference Guide 2012 Edition, including all manufacturers’ submission forms and templates, available on the PDCI Market Access website.
The online version of this publication can be accessed by anyone within the subscribing organization.
To order your subscription to the C-MAP™ Canadian Drug Benefit Plans Reference Guide, please use our order form or contact Courtney Nelson at (613) 742-8225 x26 or e-mail c-map@pdci.ca or FAX us your order at (613) 742-7675.
The subscription cost of $5,950.00 CDN, plus HST/ GST for Canadian orders, includes delivery within Canada. For orders outside of Canada the cost is $5,950.00 US.
Additional copies are available to the same subscriber at a reduced rate of $1,950.00 CDN plus HST/GST within Canada and $1,950.00 US outside of Canada.
Other PDCI Market Access C-MAP™ Services
Login to C-MAP™ Canadian Drug Benefit Plans
Provincial and NIHB Formulary Publishing Dates
